164 related articles for article (PubMed ID: 34738648)
1. Doing better with functional gastrointestinal disorders? Profiling gut microbiota and circulating antibodies to CdtB and vinculin.
Bonfrate L; Di Ciaula A; Portincasa P
Eur J Clin Invest; 2022 Jan; 52(1):e13702. PubMed ID: 34738648
[No Abstract] [Full Text] [Related]
2. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID).
Vasapolli R; Schulz C; Schweden M; Casèn C; Kirubakaran GT; Kirste KH; Macke L; Link A; Schütte K; Malfertheiner P
Eur J Clin Invest; 2021 Dec; 51(12):e13666. PubMed ID: 34390492
[TBL] [Abstract][Full Text] [Related]
3. Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.
Talley NJ; Holtmann G; Walker MM; Burns G; Potter M; Shah A; Jones M; Koloski NA; Keely S
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00064. PubMed ID: 31356481
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
Rezaie A; Park SC; Morales W; Marsh E; Lembo A; Kim JH; Weitsman S; Chua KS; Barlow GM; Pimentel M
Dig Dis Sci; 2017 Jun; 62(6):1480-1485. PubMed ID: 28451914
[TBL] [Abstract][Full Text] [Related]
5. Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.
Pimentel M; Morales W; Pokkunuri V; Brikos C; Kim SM; Kim SE; Triantafyllou K; Weitsman S; Marsh Z; Marsh E; Chua KS; Srinivasan S; Barlow GM; Chang C
Dig Dis Sci; 2015 May; 60(5):1195-205. PubMed ID: 25424202
[TBL] [Abstract][Full Text] [Related]
6. A definitive blood test for post-infectious irritable bowel syndrome?
Barlow GM; Rezaie A; Lin E; Pimentel M
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1197-1199. PubMed ID: 27682513
[No Abstract] [Full Text] [Related]
7. Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome.
Morales W; Triantafyllou K; Parodi G; Weitsman S; Park SC; Rezaie A; Pichetshote N; Lin E; Pimentel M
Neurogastroenterol Motil; 2020 Oct; 32(10):e13875. PubMed ID: 32436301
[TBL] [Abstract][Full Text] [Related]
8. Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome.
Zaki MES; Elhammady D; Foda Salama M; Abdelsalam M; Osman AOB
F1000Res; 2021; 10():303. PubMed ID: 34754418
[No Abstract] [Full Text] [Related]
9. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.
Morales W; Rezaie A; Barlow G; Pimentel M
Dig Dis Sci; 2019 Nov; 64(11):3115-3121. PubMed ID: 31152332
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation.
Rezaie A; Pimentel M; Cohen E
Am J Gastroenterol; 2017 Apr; 112(4):656-657. PubMed ID: 28381845
[No Abstract] [Full Text] [Related]
11. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico.
Schmulson M; Balbuena R; Corona de Law C
Rev Gastroenterol Mex; 2016; 81(4):236-239. PubMed ID: 27681080
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.
Pimentel M; Morales W; Rezaie A; Marsh E; Lembo A; Mirocha J; Leffler DA; Marsh Z; Weitsman S; Chua KS; Barlow GM; Bortey E; Forbes W; Yu A; Chang C
PLoS One; 2015; 10(5):e0126438. PubMed ID: 25970536
[TBL] [Abstract][Full Text] [Related]
13. Microbiome and Its Role in Irritable Bowel Syndrome.
Pimentel M; Lembo A
Dig Dis Sci; 2020 Mar; 65(3):829-839. PubMed ID: 32026278
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome.
Xiao L; Liu Q; Luo M; Xiong L
Front Cell Infect Microbiol; 2021; 11():729346. PubMed ID: 34631603
[TBL] [Abstract][Full Text] [Related]
15. Irritable bowel syndrome, the microbiota and the gut-brain axis.
Raskov H; Burcharth J; Pommergaard HC; Rosenberg J
Gut Microbes; 2016 Sep; 7(5):365-83. PubMed ID: 27472486
[TBL] [Abstract][Full Text] [Related]
16. Gut-Brain-Microbiota Axis: Antibiotics and Functional Gastrointestinal Disorders.
Karakan T; Ozkul C; Küpeli Akkol E; Bilici S; Sobarzo-Sánchez E; Capasso R
Nutrients; 2021 Jan; 13(2):. PubMed ID: 33513791
[TBL] [Abstract][Full Text] [Related]
17. Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis.
Carco C; Young W; Gearry RB; Talley NJ; McNabb WC; Roy NC
Front Cell Infect Microbiol; 2020; 10():468. PubMed ID: 33014892
[TBL] [Abstract][Full Text] [Related]
18. The Gut Microbiome in Irritable Bowel Syndrome and Other Functional Bowel Disorders.
Ringel Y
Gastroenterol Clin North Am; 2017 Mar; 46(1):91-101. PubMed ID: 28164856
[TBL] [Abstract][Full Text] [Related]
19. Dysbiosis in Functional Bowel Disorders.
Enck P; Mazurak N
Ann Nutr Metab; 2018; 72(4):296-306. PubMed ID: 29694952
[TBL] [Abstract][Full Text] [Related]
20. Fecal microbiota transplantation for gastrointestinal disorders.
Malikowski T; Khanna S; Pardi DS
Curr Opin Gastroenterol; 2017 Jan; 33(1):8-13. PubMed ID: 28134687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
